Intracellular ISG15 is an interferon (IFN)-a/b-inducible ubiquitinlike modifier which can covalently bind other proteins in a process called ISGylation; it is an effector of IFN-a/b-dependent antiviral immunity in mice [1] [2] [3] [4] . We previously published a study describing humans with inherited ISG15 deficiency but without unusually severe viral diseases 5 . We showed that these patients were prone to mycobacterial disease and that human ISG15 was non-redundant as an extracellular IFN-c-inducing molecule. We show here that ISG15-deficient patients also display unanticipated cellular, immunological and clinical signs of enhanced IFN-a/b immunity, reminiscent of the Mendelian autoinflammatory interferonopathies Aicardi-Goutières syndrome and spondyloenchondrodysplasia [6] [7] [8] [9] . We further show that an absence of intracellular ISG15 in the patients' cells prevents the accumulation of USP18 10, 11 , a potent negative regulator of IFN-a/b signalling, resulting in the enhancement and amplification of IFNa/b responses. Human ISG15, therefore, is not only redundant for antiviral immunity, but is a key negative regulator of IFN-a/b immunity. In humans, intracellular ISG15 is IFN-a/b-inducible not to serve as a substrate for ISGylation-dependent antiviral immunity, but to ensure USP18-dependent regulation of IFN-a/b and prevention of IFN-a/b-dependent autoinflammation.
Intracellular ISG15 is an interferon (IFN)-a/b-inducible ubiquitinlike modifier which can covalently bind other proteins in a process called ISGylation; it is an effector of IFN-a/b-dependent antiviral immunity in mice [1] [2] [3] [4] . We previously published a study describing humans with inherited ISG15 deficiency but without unusually severe viral diseases 5 . We showed that these patients were prone to mycobacterial disease and that human ISG15 was non-redundant as an extracellular IFN-c-inducing molecule. We show here that ISG15-deficient patients also display unanticipated cellular, immunological and clinical signs of enhanced IFN-a/b immunity, reminiscent of the Mendelian autoinflammatory interferonopathies Aicardi-Goutières syndrome and spondyloenchondrodysplasia [6] [7] [8] [9] . We further show that an absence of intracellular ISG15 in the patients' cells prevents the accumulation of USP18 10, 11 , a potent negative regulator of IFN-a/b signalling, resulting in the enhancement and amplification of IFNa/b responses. Human ISG15, therefore, is not only redundant for antiviral immunity, but is a key negative regulator of IFN-a/b immunity. In humans, intracellular ISG15 is IFN-a/b-inducible not to serve as a substrate for ISGylation-dependent antiviral immunity, but to ensure USP18-dependent regulation of IFN-a/b and prevention of IFN-a/b-dependent autoinflammation.
Calcification of the cerebral basal ganglia during childhood is an important radiological sign associated with a range of genetic and nongenetic states 12, 13 . In Fahr's disease, also known as idiopathic basal ganglia calcification (IBGC) [14] [15] [16] [17] , the genetic causes identified are germline mutations of the SLC20A2, PDGFB and PDGFRB genes 15, 16 . Intracranial calcification is also a well recognized feature of a group of Mendelian autoinflammatory diseases associated with upregulation of IFN-a/b signalling 8, 18 , including Aicardi-Goutières syndrome (AGS) and spondyloenchondromatosis (SPENCD), in particular. We investigated three siblings from China with IBGC. The eldest child (P4) died during an episode of epileptic seizures at the age of 13 years (Supplementary Information, case report). The other two siblings, currently aged 11 (P6) and 13 (P5) years, have suffered only occasional seizures. Despite having been exposed to common childhood viruses (Extended Data Table 1 ), these children have experienced no severe infectious disease. Whole-exome sequencing (WES) of P5 and P6 and their healthy mother identified only one common nonsense homozygous mutation, which had not been reported in public databases or in in-house WES data for 1,500 other individuals (Extended Data Table 2 ). This variant was in exon 2 of ISG15: c.163C.T/163C.T (p.Gln 55*/Gln 55*; asterisks denote stop codons). Familial segregation was consistent with an autosomal recessive mode of inheritance (Fig. 1a, b and Extended Data Fig. 1a ).
This observation was surprising, as we recently described three unrelated children from two families from Turkey and Iran who were homozygous for loss-of-function mutations of ISG15
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. These patients (P1, P2 and P3, now aged 17, 14 and 17 years, respectively) displayed clinical disease caused by the BCG vaccine, which, in otherwise healthy individuals, defines Mendelian susceptibility to mycobacterial disease (MSMD), a rare disorder characterized by severe clinical disease following infection with weakly virulent mycobacteria 19, 20 . In these patients, MSMD resulted from insufficient ISG15-dependent IFN-c production 21 . These patients displayed no severe viral disease 2 . Following the identification of ISG15 mutations in Chinese children with a putative diagnosis of IBGC, we performed computed tomography (CT) scans on the Iranian and Turkish ISG15-deficient MSMD patients. We found that P1 and P2 displayed calcification of the basal ganglia, with CT imaging in P3 also showing calcification along the cerebral falx (Fig. 1c) . The ISG15-deficient patients from China were not vaccinated with BCG at birth, consistent with their current lack of an MSMD phenotype. The c.163C.T/163C.T mutant allele showed no ISG15 protein on western blots (Extended Data  Fig. 1b ). In total, six patients (P4 with inferred genotype) with IBGC *These authors contributed equally to this work. 1These authors jointly supervised this work. C o n t r o ls P 1 , P 2 , P 3 C o n t r o ls P 5 , P 6
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Figure 2 | High levels of interferon-stimulated gene expression in ISG15-deficient individuals. a, Relative mRNA levels for IFI27, IFI44L, IFIT1, ISG15, RSAD2 and SIGLEC1 in peripheral blood from patients (n 5 3) or controls (C) (n 5 24) or in peripheral blood mononuclear cells (PBMCs) from family members (wild type and heterozygous for ISG15 deficiency) (n 5 2) and patients (n 5 2), as assessed by RT-qPCR, comparison done with unpaired t-tests. ***P , 0.0001; horizontal bars represent means; RQ defined in reference to C1 unstimulated condition. b, hTert-immortalized fibroblasts from C1, C16, C18, a NEMO 2/2 subject (as a negative control due to known hyporesponsiveness), P1 and P2 were treated with the indicated doses of IFNa2b for 12 h, washed with PBS and left to rest for 36 h, after which relative mRNA levels were assessed. b shows a representative experiment of three performed. GUS is used as a housekeeping control gene. NS, not stimulated. c, The same experimental procedure as in b was followed, but the mRNA was used for a microarray experiment, for C1, C6, C16, P1, P2 and P3 cells, with green indicating relative upregulation and red indicating downregulation of the probe concerned. d, In the same experimental setup, we used lentiviral particles containing luciferase-RFP (red fluorescent protein) or wild-type ISG15-RFP genes to transduce hTert-immortalized fibroblasts and then assessed mRNA levels for IFIT1 and MX1 by RT-qPCR. Panel d shows one representative experiment of three performed, where (2) denotes not transduced conditions.
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from three kindreds from China, Iran and Turkey were found to have only homozygous rare and null ISG15 mutant alleles in common (Extended Data Table 3 ). These findings strongly suggest that the three ISG15 alleles identified are disease-causing, not only for MSMD, but also for IBGC, an intracranial calcification phenotype unrelated to any obvious cerebral infection.
We next investigated whether enhanced IFN-a/b immunity might account for both the lack of antiviral immunodeficiency 5 and the intracranial calcification, as in patients with autoinflammatory AGS and SPENCD 18 . AGS-and SPENCD-causing mutations can lead to high levels of IFN-a/b in the blood and cerebrospinal fluid, and an upregulation of interferon-stimulated genes 9 . Such an IFN-a/b signature is also observed in patients with the autoimmune disorder systemic lupus erythematosus (SLE), which is sometimes associated with basal ganglia calcification and may be allelic with AGS in rare cases 6, 22, 23 . We determined the expression levels of six interferon-stimulated genes reported to be upregulated in patients with AGS 7 . IFI27, IFI44L, IFIT1, ISG15, RSAD2 and SIGLEC1 transcripts were measured in peripheral blood or peripheral blood mononuclear cells from ISG15-deficient patients and controls. Notably, all ISG15-deficient patients, like patients with AGS, had significantly higher levels of interferon-stimulated gene messenger RNA than unaffected relatives or healthy controls (Fig. 2a) . The two Chinese patients who displayed seizures (P5 and P6) also had detectable IFN-a antiviral activity in their plasma (Extended Data Fig. 1c, d ). These findings indicate that the constitutive enhancement of IFN-a/b activity characterizes ISG15 deficiency, in addition to AGS and SPENCD. All three of these conditions have the same prominent radiological sign, intracranial calcification.
ISG15 is an IFN-a/b-inducible ubiquitin-like protein that can be conjugated to many intracellular substrates via ISGylation 1, 3, 4, [24] [25] [26] ; we wondered how and why ISG15 deficiency would be associated with enhanced IFN-a/b immunity. We investigated the relationship between ISG15 deficiency and enhanced IFN-a/b immunity by monitoring the IFN-a response of hTert-immortalized fibroblasts from P1, P2, P3 and controls by reverse transcription with quantitative PCR (RT-qPCR) and genome-wide microarray analyses (Fig. 2b, c and Extended Data Table 4 ). The relative levels of 78 transcripts, including 20 canonical interferonstimulated genes (including RSAD2, IFI27, OAS3, IFI44, USP18, IFIT1 and MX1; Extended Data Table 4) were significantly higher in patients than in controls. This in vitro phenotype was rescued by transduction with wild-type ISG15 (Fig. 2d) or with ISG15(DGG), a mutant incapable of conjugation (Extended Data Fig. 2a ) 5 . We excluded the involvement of secreted ISG15 (Extended Data Fig. 2b ). Consistent with mRNA levels, cells from patients expressed more MX1 and IFIT1 proteins than control cells (Fig. 3a, b) . Remarkably, however, levels of USP18 were low in patients' cells (Fig. 3a, b) , despite their higher levels of USP18 mRNA ( Fig. 2c and Extended Data Table 4 ). Similar data were obtained for patient-derived Epstein-Barr virus (EBV)-transformed B cells and Simian virus 40 (SV40)-transformed cell lines, as well as for fibrosarcoma cells (HLLR1-1.4) and a human epithelial cell line, WISH, in which ISG15 was silenced (Extended Data Fig. 3a, b, c) . These results demonstrate a positive impact of ISG15 deficiency on the IFN-a/b response and suggest the possible involvement of USP18.
USP18 is an interferon-stimulated gene, an isopeptidase and a potent negative regulator of IFN-a signalling 10, 27, 28 . We therefore hypothesized that, in the absence of ISG15, IFN-a/b signalling would be inadequately attenuated due to insufficient USP18. Indeed, in patients' cells, STAT1 and STAT2 were more persistently phosphorylated and IFIT1 and MX1 levels were higher than in controls, whereas USP18 levels were low (Fig. 3a, b and Extended Data Fig. 3a) . The same was observed following the knockdown of USP18 and/or ISG15 expression in HLLR1-1.4 cells primed with IFN-b (Fig. 3c) . ISG15 appeared to act in its unconjugated free form, since silencing of UBE1L or of other ISGylation enzymes failed to reduce USP18 levels ( Fig. 3d and Extended Data Fig. 3d ) and patients' cells transduced with wild-type ISG15 or ISG15(DGG) exhibited attenuated levels of interferon-stimulated-gene transcripts and proteins (Extended Data Fig. 2a and Fig. 3e ). These data indicate that intracellular free ISG15 downregulates the IFN-a/b response by maintaining levels of the negative-feedback regulator USP18.
We then investigated the mechanism by which ISG15 regulates USP18. We measured the translation-independent decay of USP18 in hTert fibroblasts. In cells lacking ISG15, unlike control cells, USP18 levels began to decline after as little as one hour of cycloheximide (CHX) treatment ( Fig. 4a and Extended Data Fig. 4a, b) . This phenotype was reversed by transduction of patients' cells with wild-type ISG15 or ISG15(DGG) constructs (Fig. 4b and Extended Data Fig. 4c) . In HEK293T cells, 
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co-transfection of USP18 with either wild-type ISG15 or ISG15(DGG) resulted in augmented USP18 protein levels (Fig. 4c) . Co-transfection of USP18 with ubiquitin led to strong ubiquitination of USP18 (Fig. 4d , lane 5 and Extended Data Fig. 4d ), as previously reported 11 . The coexpression of either wild-type ISG15 or ISG15(DGG) with USP18 and ubiquitin resulted in markedly lower levels of USP18 ubiquitination (Fig. 4d, lanes 9-11 and Extended Data Fig. 4e ) and larger total amounts of USP18. Overall, these data indicate that free intracellular ISG15 antagonizes USP18 ubiquitination and degradation, thereby promoting the stability and function of this protein.
USP18 is subject to S-phase kinase-associated protein 2 (SKP2)-mediated proteolysis 11, 29 . We therefore analysed the impact of ISG15 on SKP2-mediated USP18 degradation. The formation of the USP18-SKP2 complex (Fig. 4e, lane 8) , was prevented by co-expression of ISG15 (lane 10 versus lane 8) and ISG15 co-immunoprecipitated with USP18 independently of SKP2 expression (lanes 9 and 10). Finally, we assessed IFN-induced USP18 accumulation in cells silenced for SKP2. At 24 h and beyond, USP18 levels were higher in SKP2-silenced than in unsilenced cells (Fig. 4f and Extended Data Fig. 4f ). These results suggest that ISG15 can antagonize SKP2-mediated proteolysis of USP18, although the involvement of other E3 ligases cannot be excluded. In the absence of ISG15, USP18 proteolysis is more rapid, driving the dysregulated IFN-a/b response and resulting in both the blood IFN-a/b signature and brain calcifications seen in the patients.
In conclusion, we have shown that all six ISG15-deficient children identified to date display abnormally strong IFN-a/b immunity, as demonstrated by their high levels of circulating IFN-a and/or leukocyte interferon-stimulated genes. As in patients with AGS and SPENCD 30 , ISG15-deficient individuals display marked intracranial calcification. Three of the six ISG15-deficient individuals experienced epileptic seizures, which were lethal in one case. These patients also had autoantibody levels higher than those in age-matched controls (Extended Data  Fig. 5 ). We found that ISG15 deficiency led to reduced levels of the negative regulator USP18 because of increased proteolysis due, at least in part, to SKP2-mediated ubiquitination, resulting in stronger responses to IFN-a/b and an ensuing amplification of IFN-a/b-induced responses. The observed enhancement of cellular responses to IFN-a/b provides an explanation for the lack of overt viral infection phenotypes in patients with ISG15 deficiency 5 . More importantly, human ISG15 is not only redundant for antiviral immunity in these patients, it is a key negative regulator of IFN-a/b. The role of ISG15 in stabilizing USP18 is essential and independent of conjugation. We have not tested whether ISGylated proteins might also stabilize USP18. The broad susceptibility to viral infections of ISG15-deficient mice 2 but not humans 21 may be due to different biochemical properties of murine versus human ISG15 and/ or USP18, affecting their interaction potential. Simultaneously, the lack of free extracellular ISG15 resulted in lower IFN-c production by lymphocytes, thereby underlying MSMD in these patients 5 . The phenotypic dichotomy of this monogenic disease, with both autoimmunity and MSMD, probably reflects the functional dichotomy of intracellular versus extracellular ISG15, respectively. There is currently no evidence that IFN-a/b-inducible human intracellular ISG15 exerts antiviral effects on documented viral infections via ISGylation. On the contrary, we show that IFN-a/b-inducible ISG15 is essential to negatively regulate IFN-a/b responses via USP18 stabilization, thereby preventing autoinflammatory consequences of uncontrolled IFN-a/b amplification.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 

METHODS
Exome capture, sequencing, alignments and variant calling. Exome sequencing was performed on two affected sisters and their unaffected mother. Libraries were prepared following the kit manufacturer's protocol. In brief, we randomly fragmented 3 mg of purified genomic DNA with an ultrasonoscope (Covaris, Massachusetts, USA) to produce fragments of 150,200 base pairs (bp) in length. The shotgun library was then subjected to hybridization with the Agilent SureSelect Human All Exon 50Mb kit (Agilent Technologies, California, USA) for exome capture, followed by several cycles of amplification before quality control with a 2100 Bioanalyzer (Agilent Technologies) and quantification by RT-qPCR with the StepOnePlus Real-Time PCR System (Life Technologies, California, USA). The final library was sequenced on an Illumina Hiseq2000 (Illumina, California, USA) with 90-bp paired-end reads, following the Hiseq2000 protocol. We used BWA Aligner to align the sequences with the human genome reference sequence (hg18 build). Downstream processing was carried out with the Genome analysis toolkit (GATK) SAMtools and Picard Tools (http://picard.sourceforge.net). Substitution calls were made with a GATK Unified Genotyper, whereas insertion/deletion (indel) calls were made with a GATK Indel GenotyperV2. All calls with a read coverage #23 and a Phred-scaled SNP quality #20 were filtered out. All the variants were annotated with the GATK Genomic Annotator. For filtering purposes, we used the 1000 Genomes and EVS databases, and an in-house exome database containing data for over 1,000 individuals. For the comparative analysis of P1, P2, P5 and P6, we removed variants with less than six reads and a mapping quality of less than 40 (per GATK), and we used the dbSNP database in addition to the 1000 Genomes and EVS databases. qPCR and microarray analysis. We assessed the expression of six known interferon-stimulated genes in whole blood. Total RNA was extracted from whole blood with the PAXgene (PreAnalytix) RNA isolation kit. RNA concentration was assessed with a spectrophotometer (FLUOstar Omega, Labtech). Quantitative reverse transcription PCR analysis was performed with the TaqMan Universal PCR Master Mix (Applied Biosystems) and cDNA derived from 40 ng of total RNA. The relative abundance of target transcripts, measured with TaqMan probes for IFI27 (Hs01086370_ m1), IFI44L (Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15 (Hs00192713_m1), RSAD2 (Hs01057264_m1), and SIGLEC1 (Hs00988063_m1), was normalized with respect to the expression of HPRT1 (Hs03929096_g1) and 18S (Hs999999001_s1) and assessed with Applied Biosystems StepOne Software v2.1 and Applied Biosystems Data Assist Software v3.01. Data for the patients are expressed relative to mean values for 23 normal controls. For PBMCs, total RNA was extracted with the RNeasy Mini kit (Qiagen). It was not possible to standardize the amount of RNA added to the cDNA synthesis reaction, but expression was nonetheless normalized with respect to the level of expression of HPRT1 (Hs03929096_g1) and 18S (Hs999999001_ s1). For PBMCs and hTert fibroblasts, total RNA was extracted with the RNeasy Mini kit (Qiagen) and the standard protocol for hybridization to Affymetrix HTA 2.0 chips was performed. In microarray experiments, we used 1,000 IU ml 21 IFNa2b as a stimulus. Affymetrix Expression Console and Transcriptome Analysis Console were used for analysis. Upregulation or downregulation was defined as significant if expression was twofold higher or lower for P1, P2 and P3 IFN-a2b-stimulated cells than for C1, C6 and C18 IFN-a2b-stimulated cells. Cell lines and reagents. Human fibrosarcoma HLLR1-1.4 cells, which have been described elsewhere 25 , were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented with 10% fetal calf serum, hypoxanthine, thymidine and aminopterin (HAT) and 400 mg ml 21 G418 (Gibco). WISH amnion-derived epithelial cells, HEK293T cells, SV40-transformed and hTert-immortalized fibroblasts from controls and patients were cultured in DMEM supplemented with 10% fetal calf serum. EBV-transformed B cells from patient P1 and controls were cultured in RPMI medium supplemented with 10% fetal calf serum. Recombinant IFN-a2b was a gift from D. Gewert (Wellcome Foundation, Beckenham, Kent, UK; now at BioLauncher Ltd, Cambridge, UK) or was purchased from Schering; IFN-b was obtained from Biogen Idec, Cambridge, MA, USA. IFNs were purified to specific activities of .10 8 units per mg of protein. Cycloheximide (CHX) (Sigma) was used at a concentration of 20 mg ml
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. Plasmids and transfection. HEK293T cells were transiently transfected with the FuGENE6 system (Roche Applied Science). The pMET7-USP18 expression vector has been described elsewhere 27 ; pcDNA31His 6 -3xFlagISG15 (Fig. 4d, e and Extended Data Fig. 4d ) was provided by J. M. Huibregtse (University of Texas at Austin, TX, USA), pBabe-3xFlag6His-ISG15 (BUG3354) and pBabe-3xFlag6His-ISG15(DGG) (BUG3355) (Fig.4c and Extended Data Fig. 4e ) were derived from this plasmid; pcDNA3 Flag-SKP2 and HA-ubiquitin constructs were obtained from E. Bianchi (Institut Pasteur, Paris, France). In co-transfection experiments, empty vector was added to keep the total amount of DNA constant. siRNA-mediated silencing. USP18, UBE1L, UbcH8, HERC5, SKP2 ON-TARGETplus SMART pools and a control siRNA (ON-TARGETplus non-targeting pool) were obtained from Dharmacon. Three individual ISG15-targeting siRNAs from Sigma were tested: ISG15#9, GGACAAAUGCGACGAACCU; ISG15#11, GCAGAUCA CCCAGAAGAUU; ISG15#12, GCAACGAAUUCCAGGUGUC. All efficiently targeted ISG15 transcripts. In all the experiments shown, ISG15#12 was used. Cells were transfected with 25 nM siRNA for 24 h in the presence of the Lipofectamine RNAi max reagent (Invitrogen), according to the manufacturer's instructions. Cells were then stimulated with IFN. Protein analyses. Cells were lysed in modified RIPA buffer (50 mM Tris/HCl pH 8, 200 mM NaCl, 1% Nonidet P40, 0.5% deoxycholate, 0.05% SDS, 2 mM EDTA), 1 mM orthovanadate and a protease inhibitor cocktail and subjected to western blotting. For co-immunoprecipitation, cells were lysed in 50 mM Tris, pH 6.8, 0.5% Nonidet P40, 200 mM NaCl, 10% glycerol, 1 mM EDTA and a protease inhibitor cocktail. For the analysis of USP18 ubiquitination (Fig. 4d and Extended Data Fig. 4d and 4e), cells were lysed in modified RIPA buffer and a protease inhibitor cocktail, and USP18 was immunoprecipitated from post-nuclear lysates for 2 h at 4 uC. It was then subjected to protein A capture and western blotting. . In brief, diluted serum samples were incubated in duplicate with the autoantigen array and the autoantibodies binding to the antigens were detected with Cy3 and Cy5 fluorescent labelled anti-Ig antibodies (IgG and IgA), by the generation of TIFF images. Genepix Pro 6.0 software was used to analyse the images. Net fluorescence intensities (defined as fluorescence intensity for the spot minus background fluorescence intensity) for duplicate spots were averaged. The signal-to-noise ratio (SNR) was used as a quantitative measurement of the ability to resolve true signal from background noise and SNR values of at least 3 were considered to differentiate a true signal from background noise.
Data were normalized as follows: immunoglobulin positive control (IgG or IgA) values across all samples were averaged and the positive control value for each sample was divided by the mean positive control value to generate a normalization factor for each sample. Each signal was then multiplied by the normalization factor for each block (sample). LETTER RESEARCH
